BioCryst is a biotechnology company that develops and commercializes medicines for rare diseases, particularly hereditary angioedema (HAE) and other orphan indications. The company's primary revenue driver is ORLADEYO, an oral plasma kallikrein inhibitor for HAE prevention that generates sales through specialty pharmacy distribution in the United States and through regional licensing partnerships internationally with tiered royalty structures. Beyond ORLADEYO, BioCryst maintains a clinical pipeline of oral small molecules and injectable protein therapeutics targeting rare diseases, including assets acquired through strategic business development, alongside approved antiviral products for influenza, generating revenue from government contracts and international partnerships while leveraging established commercial infrastructure and patent protections for competitive positioning in rare disease markets.